Abstract. Chronic gouty arthritis, caused by a persistent increase in, and the deposition of, soluble uric acid (sUA), can induce pathological chondrocyte destruction; however, the effects of urate transport and intracellular sUA on chondrocyte functionality and viability are yet to be fully determined. Thus, the aim of the present study was to investigate the presence and functionality of a urate transport system in chondrocytes. The expression profiles of two primary urate reabsorptive transporters, glucose transporter 9 (GluT9) and urate transporter 1 (URAT1), in human articular cartilage and chondrocyte cell lines were examined via western blotting, reverse transcription-quantitative PCR, immunohistochemistry and immunofluorescence. Then, chondrocytes were incubated with exogenous sUA at increasing concentrations. Negative control assays were conducted via the specific knockdown of GluT9 and URAT1 with lentiviral short hairpin (sh)RNAs, and by pretreatment with benzbromarone, a known inhibitor of the two transporters. Intracellular UA concentrations were measured using colorimetric assays. The expression levels of GLUT9 and URAT1 were determined in cartilage tissues and chondrocyte cell lines. Incubation of chondrocytes with sUA led to a concentration-dependent increase in intracellular urate concentrations, which was inhibited by GluT9 or URAT1 knockdown, or by benzbromarone pretreatment (27.13±2.70, 44.22±2.34 and 58.46±2.32% reduction, respectively). In particular, benzbromarone further decreased the already-reduced intracellular UA concentrations in Hc-shGluT9 and Hc-shURAT1 cells by 46.79±2.46 and 39.79±2.22%, respectively. Cells overexpressing GluT9 and URAT1 were used as the positive cell control, which showed increased intracellular UA concentrations that could be reversed by treatment with benzbromarone. In conclusion, chondrocytes may possess an active UA transport system. GluT9 and URAT1 functioned synergistically to transport UA into the chondrocyte cytoplasm, which was inhibited by specific gene knockdowns and drug-induced inhibition. These results may be fundamental in the further investigation of the pathological changes to chondrocytes induced by sUA during gouty arthritis, and identified UA transport processes as potential targets for the early control of chronic gouty arthritis.

Introduction

Chronic gouty arthritis is a crystal-forming type of arthritis that causes severe inflammation and irreversible bone erosion, in which chondrocytes may serve an important role. Patients with gout display severe cartilage destruction and empty chondrocyte lacunae upon histopathological examination (1). A number of studies have demonstrated reduced cell viability and impaired functionality of chondrocytes following stimulation with monosodium urate monohydrate (MSU) crystals (1-3); however, MSU is precipitated from synovial soluble uric acid (sUA) in vivo only under certain conditions (4). Thus, the impact of sUA on chondrocytes may occur prior to MSU...
formation in gout, which is characterized by hyperuricemia. It was reported that sUA could lead to cellular dysfunction and a loss of viability in numerous cell types, including renal tubular cells (5), endothelial cells (6), vascular smooth muscle cells (7,8), hepatocytes (9), pancreatic β-cells (10,11) and adipocytes (12); however, at present, few studies have focused on the effects of high levels of sUA on chondrocytes.

The oxidative properties of sUA require entry into the intracellular environment; previous experiments have demonstrated that inhibiting the entry of sUA into the cytoplasm blocked sUA-induced oxidative damage (5-9,12-14). Glucose transporter 9 (GLUT9) and urate transporter 1 (URAT1), the most notable reabsorptive urate transporters, regulate the access of sUA into the cytoplasm under normal and pathological conditions (15). GLUT9 serves a major role in UA homeostasis via its dual role in UA handling in the kidneys and uptake in the liver (16). In the Chinese population, a missense mutation in the GLUT9 gene was associated with chronic gouty arthritis (17); however, its UA transport capacity in chondrocytes and further actions in gout-associated cartilage damage are yet to be determined. URAT1 has been reported to be expressed in renal tubular cells (18), pancreatic β-cells (10,11), endothelial cells (6), vascular smooth muscle cells (19) and adipocytes (12). The expression and uric transport function of URAT1 in chondrocytes have not been investigated.

To the best of our knowledge, whether there is a UA transport process in chondrocytes has not been previously studied, and the contribution of UA transport in chondrocytes to gouty arthritis is yet to be identified. Therefore, the expression profiles of GLUT9 and URAT1, and their contribution to UA transport capacity in chondrocytes were investigated in the present study.

Materials and methods

Tissue samples. The present study was approved by the Institutional Review Board of Peking Union Medical College Hospital (perm no. ZS-1445), and was conducted in accordance with the Declaration of Helsinki. Human articular cartilage (AC) was obtained from patients at the Orthopedic Department of the Peking Union Medical College Hospital between December 2017 and March 2018. All patients signed informed consent prior to the collection of samples. The inclusion criteria were a diagnosis of femoral neck fracture due to trauma and a requirement for a total hip replacement. Patients were excluded if they exhibited: i) Hyperuricemia; ii) gout; iii) arthritis; iv) rheumatoid arthritis; v) femoral head necrosis of any origin; and vi) cancer. AC samples were obtained from the otherwise discarded femoral head. AC tissue was immediately snap-frozen in liquid nitrogen, with the remaining sample immersed in 10% formalin at room temperature overnight for paraffin embedding. The clinical characteristics of the 5 patients from whom the AC samples were obtained are presented in Table S1.

Immunohistochemistry. Immunohistochemical assays were performed as previously described (20). Cartilage sections (thickness, 5 µm) were immersed at room temperature within 3% hydrogen peroxide in the dark for 25 min and then 3% BSA (cat. no. A8010; Beijing Solarbio Science & Technology Co., Ltd.) for 30 min at room temperature to block the endogenous peroxidase and non-specific protein, respectively. Then the sections were incubated at 4°C overnight with rabbit polyclonal antibodies against collagen II (1:100; cat. no. ab34712; Abcam), human GLUT9 (1:100; cat. no. ab223470; Abcam), and human URAT1 (1:100; cat. no. 14937-1-AP; ProteinTech Group, Inc.). PBS was used as a negative control (Fig. S1). Sections were labeled with horseradish peroxidase (HRP)-conjugated goat anti-rabbit immunoglobulin G heavy and light chain (IgG H&L) secondary antibody (1:1,000; cat. no. ab6721; Abcam) at room temperature for 50 min. Resolution with 3,3′-diaminobenzidine substrate (cat. no. DA1010; Beijing Solarbio Science & Technology Co., Ltd.) was guided microscopically. Cell nuclei were counterstained with aqueous hematoxylin at room temperature for 3 min. Digital images were captured using a Nikon Microphot-FX microscope (magnification x100 and x200; Nikon Corporation).

Human articular chondrocyte cell line and gene knockdown. The human articular chondrocyte (HC-a) cell line, derived from human ACs, was purchased from ScienCell Research Laboratories, Inc. (cat. no. 4650). Cells were cultured at 37°C in an humidified incubator with 5% CO₂ with complete chondrocyte medium that contained 5% FBS, 1% chondrocyte growth supplement and 1% penicillin/streptomycin (cat. no. 4651; ScienCell Research Laboratories, Inc.).

Gene knockdown was performed as previously described (21). HC-a cells were cultured 24-well plates until they reached 1x10⁶ cells/well, and the medium was replaced fresh medium containing 6 µg/ml Polybrene® (cat. no. sc-134220; Santa Cruz Biotechnology, Inc.). A total of 10 µl lentiviral particles containing short hairpin (sh)RNA against SLC2A9 (the gene encoding GLUT9; cat. no. sc-105399-V; Santa Cruz Biotechnology, Inc.) or SLC22A1J (the gene encoding URAT1; cat. no. sc-96373-V; Santa Cruz Biotechnology, Inc.) were then added and incubated for at 37°C 24 h. Scrambled vector (cat. no. sc-108080; Santa Cruz Biotechnology, Inc.) was used as a negative control. Cells were then cultured in fresh complete medium and allowed to grow to 90% confluency for ~24 h.

Humane embryonic kidney cells 293 and gene overexpression. 293 cells were purchased from the National Infrastructure of Cell Line Resource (cat. no. 3111C0001CC000010). 293 cells were cultured at 37°C with 5% CO₂ in HyClone™ Minimal Essential Medium with Earle's (cat. no. SH30024.01; Beijing Solarbio Science & Technology Co., Ltd.) supplemented with 10% FBS (cat. no. P30-3302; PAN-Biotech).

293 cells were cultured on 24-well plates to a density of 1x10⁶ cells/well and then subjected to gene overexpression as previously reported (22). The recombinant plasmids SLC2A9 pcDNA3.1-T2A-EGFP (Fig. S2) and SLC22A1J pcDNA3.1-T2A-EGFP (Fig. S3) were purchased from Hanbio Biotechnology Co., Ltd. Briefly, 0.8 µg plasmids were mixed with 2 µl LipoFiter™ liposomal transfection reagent (cat. no. HB-TRLF-1000; Hanbio Biotechnology Co., Ltd.) for 20 min at room temperature and then added to cells. Empty vector (pcDNA3.1-T2A-EGFP; Hanbio Biotechnology Co., Ltd.) was used as a negative control. Following transduction
for 6 h, the medium was replaced with complete medium. Cells were then allowed to grow to 90% confluency for ~24 h.

Reverse transcription-quantitative PCR (RT-qPCR). Total RNA was extracted with TRIzol® (cat. no. DP405-02; Tiangen Biotech Co., Ltd.) according to the manufacturer’s protocols. After converting the RNA to cDNA using a PrimeScript™ RT kit (cat. no. RR047B; Takara Biotechnology Co., Ltd.), qPCR was conducted using Bio-Rad iQ5 and SYBR Green Master Mix (cat. no. AB1750; Bio-Rad Laboratories, Inc.) under the following thermocycling conditions: 95°C for 30 sec, followed by 40 cycles of 95°C for 5 sec and 60°C for 40 sec, and then 95°C for 10 sec, 60°C for 60 sec and 95°C for 15 sec to obtain the melting curve; finally, samples were slowly heated to 99°C. The relative gene expression was quantified with the 2^(-ΔΔCq) method (23). Data were normalized to β-actin mRNA levels. The primers used were as follows: GluT9, forward 5’-ccTTG TGc TTc TC-3’; uraT1, forward 5’Gcc cGa cac caT reverse 5’-aGT GGG GTG GcT TTT aGG aT-3’. Western blot analysis. Western blotting was conducted as previously described (24). Proteins (30 μg) were separated via 10% SDS-PAGE under reducing conditions, and transferred onto nitrocellulose membranes. Following blocking with 5% skimmed milk at room temperature for 1 h, membranes were incubated with primary antibodies at 4°C overnight, and labeled with secondary antibodies at room temperature for 45 min. The primary antibodies used for western blot analysis included: Rabbit polyclonal antibodies to collagen II (1:1,000; cat. no. ab34712; Abcam), human GLUT9 (1:1,000; cat. no. ab223470; Abcam), and human URAT1 (1:600; cat. no. 14937-1-AP; Proteintech Group, Inc.). Mouse polyclonal antibodies against β-actin (1:1,000; cat. no. ab8226; Abcam), Na-K ATPase (EP1845Y; 1:5,000; cat. no. ab76020; Abcam) and GAPDH (EPR16891; 1:5,000; cat. no. ab181602; Abcam) were used as loading controls for whole cell, cell membrane and cytoplasmic protein extracts, respectively. PBS was used as a negative control (Fig. S5). HRP-conjugated goat anti-rabbit IgG H&L (1:10,000; cat. no. ab6721; Abcam) and goat anti-mouse IgG H&L (1:10,000; cat. no. ab205719; Abcam) antibodies were used as the secondary antibodies. Chemiluminescence was performed using Pierce™ Fast Western Blot ECL substrate (cat. no. 35055; Thermo Fisher Scientific, Inc.). Densitometric analysis of the band intensities was conducted using AlphaView Stand Alone (version 3.4.0, ProteinSimple) as previously described (24).

UA transport assays. Cells were cultured in 6-well plates to a density of 1x10⁶ per well and washed with Krebs-Ringer bicarbonate (KRP) buffer (cat. no. G0430; Beijing Solarbio Science & Technology Co., Ltd.). Cells were pretreated with KRP buffer containing 50 μM benzbromarone for 30 min and incubated with 1 mM benzbromarone for an additional 30 min. It was previously demonstrated that rapid UA transport occurs as early as 20 min post-incubation with UA (14), which could be inhibited by benzbromarone at a concentration of 50 μM (25,26). Thus, for UA transport assays, cells were starved in KRP for 30 min, followed by the addition of exogenous sUA (cat. no. U0881; Sigma-Aldrich; Merck KGaA) at concentrations of 0, 0.25, 0.50, 0.75 and 1 mM at 37 °C for 30 min. For inhibition assays, cells were pretreated with KRP buffer containing 50 μM benzbromarone (J&K Scientific Ltd.) at 37°C for 30 min and incubated with 1 mM sUA at 37°C for a further 30 min.

Following this incubation, supernatants were removed, cells were washed twice with cold PBS and intracellular UA concentrations were measured using Colorimetric UA assay kits (cat. no. ab65344; Abcam) according to the manufacturer’s protocols. Briefly, cells were resuspended in UA assay buffer and centrifuged at 13,000 g at 4°C for 5 min. Supernatants were collected and reaction solutions were added for 30 min at 37°C in the dark. The optical density at 570 nm was measured using a microplate reader. Standard curves were obtained with UA standards.
**Results**

**GLUT9 and URAT1 are expressed in human cartilage and HC-a chondrocyte cells.** A total of 5 AC samples were collected during the present study. The clinical characteristics of the 5 patients from whom the AC samples were obtained are presented in Table S1. The expression levels of GLUT9 and URAT1 in the 5 human AC samples were examined by western blot and immunohistochemical analyses. Collagen II expression is a characteristic of chondrocytes (27), thus the detection of collagen II indicated the presence of chondrocytes in AC samples (Figs. 1 and 2). Western blot analysis using specific antibodies against GLUT9 and URAT1 revealed positive expression in all 5 samples (Fig. 1; Table S1I). Immunohistochemical assays also revealed positive staining for GLUT9 and URAT1 in all AC samples (Fig. 2).

Furthermore, GLUT9 and URAT1 expression was observed in HC-a cells, the human articular chondrocyte cell line, via RT-qPCR (Fig. 3A), immunofluorescence (Fig. 3B) and western blot analyses (Fig. 3C; Tables S1II and SIV). Further separation of the membrane portion revealed high expression of the two transporters in the membrane protein extracts (Fig. 3D; Tables S1III and SIV), with limited expression in cytoplasmic protein extracts (Fig. 3E; Tables S1III and SIV).

**HC-a cells display a concentration-dependent UA transport process.** As the aforementioned results indicated the expression of two major urate transporters in chondrocytes, the present study then investigated the UA transport capacity of chondrocytes. sUA was added to HC-a cells at increasing concentrations (0, 0.25, 0.50, 0.75 and 1 mM), and intracellular UA concentrations were measured using colorimetric UA assays. It was demonstrated that HC-a cells displayed UA transport capacity, as evidenced by a concentration-dependent increase in intracellular UA, with a linear R² of 0.993 (Fig. 4A; Table S5V).

**UA transport is inhibited by GLUT9 and URAT1 knockdown in HC-a cells.** To study the contribution of GLUT9 and URAT1 to UA transport, HC-a cells were transduced with lentiviral particles containing shRNAs to knockdown the expression of GLUT9 (HC-shGLUT9) and URAT1 (HC-shURAT1), with knockdown demonstrated via immunofluorescence, RT-qPCR and western blot analyses (Fig. 3). Then, HC-shGLUT9 and HC-shURAT1 cells were incubated with sUA (1 mM) under the same conditions as the wildtype HC-a cells. Compared with wildtype cells, intracellular UA concentrations in HC-shGLUT9 and HC-shURAT1 cells were significantly decreased by 27.13±2.70 and 44.22±2.34%, respectively (P<0.05; Fig. 4B; Table S5VI). Cells transduced with scrambled vectors did not exhibit altered protein expression or UA transport capacity (Figs. 3 and 4; Tables S1III, SIV, and S5VI). These data confirmed there may be a role for GLUT9 and URAT1 in the UA transport capacity of chondrocytes.

**UA transport is inhibited by benzbromarone in HC-a cells.** Previous studies have reported that 50 µM benzbromarone, a widely used uricosuric agent, can reduce the UA transport capacity of GLUT9 and URAT1 by ~68% (25) and ~93% (26), respectively. Therefore, it was used to investigate the effects of the two Urate transporters in HC-a cells. The results revealed that benzbromarone treatment significantly reduced the intracellular UA concentration in HC-a cells by 58.46±2.32% (P<0.05; Fig. 4B; Table S5VI), but it did not affect protein expression or subcellular location in HC-a cells, as determined by RT-qPCR and western blot assays (Fig. 3).

In HC-shGLUT9 and HC-shURAT1 cells, whose intracellular UA concentrations were already reduced following gene knockdown, benzbromarone pretreatment further decreased intracellular UA concentrations by 46.79±2.46 and 39.79±2.22%, respectively (P<0.05; Fig. 4B; Table S5VI), suggesting that GLUT9 and URAT1 acted synergistically to mediate UA transport in HC-a cells.

**UA transport is enhanced in 293 cells overexpressing GLUT9 and URAT1, which is reversed by benzbromarone treatment.**
To verify the sensitivity of the colorimetric UA kit and as a positive cell control, GluT9 and uraT1 were overexpressed in 293 cells (Fig. 5a; Table SVII), a well-characterized UA transport assay system (14,28). Wildtype 293, GluT9-293 and uraT1-293 cells were incubated with sUA (0, 0.25, 0.50, 0.75, and 1 mM), and the intracellular UA levels were assessed. The results revealed enhanced UA transport with increasing concentrations of sUA in all 3 types of cell (r²=0.954 for wildtype cells, 0.955 for GluT9-293 cells and 0.947 for uraT1-293 cells). In addition, the intracellular UA concentrations were significantly increased in GLUT9-293 and URAT1-293 cells compared with the wildtype 293 cells at all sUA concentrations assessed (Fig. 5B; Table SVIII); however, pretreatment with benzbromarone significantly reversed the increased intracellular UA concentrations induced by the overexpression of GLUT9 and URAT1 (Fig. 5C; Table SIx). Cells transduced with empty vector did not exhibit altered protein expression or UA transport capacity (Fig. 5; Tables SVII and SIx). These findings were consistent with those of previous studies (14,28) and thus demonstrated the sensitivity of the colorimetric UA transport assay.

Discussion

In the present study, the expressions of GLUT9 and URAT1 were demonstrated in AC tissues obtained from human cartilage via immunohistochemistry and western blot analyses, and then further verified using a human cartilage chondrocyte cell line (HC-a). The two proteins were predominately expressed in the cell membrane, with limited expression in the cytoplasm. Functional studies revealed that wildtype HC-a cells exhibited a concentration-dependent increase in intracellular UA concentrations following incubation with exogenous sUA. Specific gene knockdown or functional inhibition of GLUT9 and URAT1 significantly decreased intracellular sUA. Therefore, to the best of our knowledge, the present study demonstrated for the first time that there is an active UA transport system in chondrocytes, which possessed two major urate transporters, GLUT9 and URAT1.

The confirmation of a UA transport system in chondrocytes is notable, as sUA turns into a strong pro-oxidative agent once transported into cytoplasm, and inhibiting this transport may prevent sUA-induced cell damage (5-9,12-14). Previous studies in other cell types revealed that intracellular sUA directly activates NADPH oxidase, which in turn activates the production of reactive oxygen species (ROS) (29). Increased ROS levels in turn stimulate protein kinases (MAPKs, ERKp44/42 and p38), proliferative factors (platelet-derived growth factor and transforming growth factor β) and proinflammatory transcription factors (NF-κβ), alter mitochondrial morphology and functionality, and activate endoplasmic reticulum (ER) stress (8,9,30-32), leading to cell type-specific damage. Blocking the access of sUA to the cytoplasm using UA transport inhibitors significantly prevented sUA-induced ROS production and oxidative damage (5-9,12-14). Chondrocytes are characterized by their sensitivity to oxidative stress. ROS in chondrocytes directly activated mitochondrial oxidation (33), ER stress (34) and various signaling pathways, including p38MAPK, ERK1/2 and NF-κB pathways (35), leading to alterations in cell viability and functionality. Thus, it was hypothesized that intracellular sUA may influence chondrocyte viability and functionality. The identification of a UA transport system in chondrocytes is central for research into sUA-induced changes in chondrocytes, and may support future interventions targeted against sUA-induced chondrocyte damage in patients in early stages of gout.

In the present study, GLUT9 and URAT1 were revealed to be active urate transporters in chondrocytes. Previous studies have reported that the two transporters are crucial for regulating UA homeostasis and are subject to various regulatory mechanisms. For example, at the transcriptional level, the GLUT9 promoter contains a conserved response element of STAT5b, which transduces the negative regulatory effects of growth hormone (36). Similarly, the promoter region of
URAT1 contains two GATA sites, which may be responsible for the binding of testosterone (37). In vivo studies with mice confirmed that GLUT9 expression was subject to the inhibitory effects of male-pattern growth hormone secretion (36), whereas URAT1 mRNA was 2.3 times higher in male mice than in female mice (38). In addition, IL-1β stimulation significantly increased the mRNA levels of GLUT9 in chondrocytes (39), whereas tumor suppressor p53 promoted GLUT9 mRNA levels by binding to the promoter region with increased UA transport in fibroblast cell lines and lung cancer cells (40). The promoter region of URAT1 also contains 2 activating protein (AP)-1 sites, 4 AP-4 sites, 1 hepatocyte nuclear factor 1 site and a CCAAT enhancer binding protein β site (37), indicating its potential for regulation. Furthermore, a hyperuricemic mouse model exhibited decreased levels of URAT1 mRNA, whereas obese mice possessed increased levels of URAT1 Mrna (41,42). These results highlight the role of the two transporters in maintaining UA homeostasis during different physiological and pathological conditions. At the post-translational level, the two proteins require targeting to the cell membrane, which may be regulated by endocytic processes. The N-terminal dileucine motif in GLUT9 may be involved in endocytic regulation, as this motif was responsible for the endocytosis of GLUT4, GLUT8 and GLUT12 (43).
293 cells, Wu et al (44) reported that Numb, a clathrin-coated pit adapter protein, bound to URAT1 via its phosphotyrosine-binding domain, facilitating the endocytic regulation of URAT1 under normal and pathological conditions. Due to the importance of plasma membrane density in transporter function, improved understanding of endocytic processes that regulate GluT9 and URAT1 spatial density may reveal novel trafficking processes that can be targeted to control UA transport in chondrocytes.

At the protein level, the activities of the two proteins are regulated by a number of drugs. Among these, benz bromarone is a strong uricosuric agent that inhibits GluT9 (IC_{50} ~14.2 µmol/l) and URAT1 (IC_{50} ~0.45 µmol/l) in irreversible manners (45,46). The mechanism of benz bromarone is considered functional. In GluT9, the binding pocket is formed by critical transmembrane domain 7 (TM7) and other residues, including N429, C181, C301, C459, C128, I355 and W110 (47,48). Among these residues, C181, the cysteine residue that faces the translocation pore, may be responsible for inhibitor binding and substrate transport function, as proposed by a protein homological study (48). In URAT1, 3 key residues, F365 on TM7, S35 on TM1 and I481 on TM11, form a plane in the channel that is perpendicular to the cell membrane. A loss-of-function mutation of any of these amino acids resulted in a reduced binding affinity of benz bromarone by 17-, 10-, and 5-fold, respectively. Similarly, F365 and S35 were important for uric acid binding affinity, as mutation of the two amino acids resulted in a 2.5- and 2.1-fold decrease in uric acid binding affinity, respectively. Thus, it was proposed that benz bromarone functioned by preventing substrate interactions within the central portion of the URAT1 channel (45).
The present findings revealed that neither total nor membrane expression of the two transporters was altered following incubation of HC-a cells with benz bromar onone, which supported the notion that the drug was a functional inhibitor without affecting transporter expression or subcellular location.

There were certain limitations to the present study. GLUT9 exists as one of two splicing variants, GLUT9L and GLUT9S, which differ in their N-terminals and cell distribution (49). The antibody used in the present study recognizes the C-terminal of the GLUT9 protein, and therefore could not distinguish between the two variants; however, previous studies have reported two prominent bands in chondrocytes of 60 and 50 kDa, suggesting the existence of two different splice variants (50). Furthermore, as benz bromar onone also inhibited other minor, facilitative urate transporters, including organic anion transporter (OAT)-1 (Ki 0.22 µM) (28), OAT3 (Ki 0.11 µM) (28), OAT4 (IC50 3.19 µM) (51), and OAT10 (IC50 ~20 µM) (46), these OATs may also be components of the UA transport system in chondrocytes. The expression and UA transport capacity of the minor urate transporters, as well as ATP-binding cassette subfamily G member 2, nicotinate phosphoribosyltransferase (NPT)1, NPT4 and multidrug resistance-associated protein 4 may be investigated in future studies to obtain further understanding of the UA transport system in chondrocytes. Additionally, the present study used colorimetric UA transport assays, which are qualitative, but do not allow for the assessment of UA uptake kinetics; however, the results did verify the sensitivity of the colorimetric UA transport assays in positive control 293 cells following GLUT9 and URAT1 overexpression, which was consistent with radiolabeled assays previously employed in this cell line (14,28).

Finally, the present study failed to obtain cartilage samples from patients with gout, and to explore the regulation of the two transporters during in vitro experiments, which may provide evidence regarding the pathological regulation of the two transporters. Such regulations, as well as subsequent changes in cell viability and functionality, will be the focus of future studies.

In conclusion, to the best of our knowledge, the present study is the first to report that chondrocytes obtain an active UA transport system mediated by GLUT9 and URAT1, which may be targets for pathological regulation and therapeutic interventions. The involvement of chondrocytes in gouty arthritis may be complex. Further studies into the impact of sUA on chondrocyte ROS production, viability and functionality, and UA transport regulation during normal and pathological conditions, may reveal the potential roles of urate transporters during gouty arthritis. These findings may identify promising targets in UA transport processes for the early control of chronic gouty arthritis.

Acknowledgements

Not applicable.

Funding

This study was supported by the 2016 PUMCH Science Fund for Junior Faculty (grant no. pumch-2016-2.13), the Medical Epigenetics Research Center, Chinese Academy of Medical Sciences (grant no. 2017PT31035), the CAMS Innovation Fund for Medical Sciences (grant no. 2016-I2M-1-002), and the Chinese Research Special Fund for Public Welfare industry of Health (grant no. 201502024).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

BiZ and MD designed the study and drafted the manuscript. BiZ, MD and BL conducted the majority of the experiments. BaZ and YJ enrolled the patients and collected the tissue samples. BiZ, DW and YZ analyzed the data. JC and XH interpreted the data and revised the manuscript for critical intellectual content. LZ and XZ contributed to the study design, provided assistance with the experiments and revised the manuscript. All authors read and approved the manuscript.

Ethics approval and consent to participate

This study was approved by the institutional review board of Peking Union Medical College Hospital (permit no. ZS-1445) and was conducted in accordance with the Declaration of Helsinki (2000) of the World Medical Association. All patients signed informed consent prior to tissue sample collection.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References


This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.